Emergent BioSolutions (STU:ER4) Total Liabilities : €1,049 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Total Liabilities?

Emergent BioSolutions's Total Liabilities for the quarter that ended in Mar. 2024 was €1,049 Mil.

Emergent BioSolutions's quarterly Total Liabilities declined from Sep. 2023 (€1,120.56 Mil) to Dec. 2023 (€1,076.47 Mil) and declined from Dec. 2023 (€1,076.47 Mil) to Mar. 2024 (€1,048.52 Mil).

Emergent BioSolutions's annual Total Liabilities increased from Dec. 2021 (€1,191.39 Mil) to Dec. 2022 (€1,679.00 Mil) but then declined from Dec. 2022 (€1,679.00 Mil) to Dec. 2023 (€1,076.47 Mil).

Emergent BioSolutions Total Liabilities Historical Data

The historical data trend for Emergent BioSolutions's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Total Liabilities Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,114.92

1,180.56

1,191.39

1,679.00

1,076.47

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,631.89	1,128.37	1,120.56	1,076.47	1,048.52

Emergent BioSolutions Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Emergent BioSolutions's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	597.242	+	(409.44	+	26.502
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	43.282	+	0)
	=	1,076

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1671.874	-	595.408
	=	1,076

Emergent BioSolutions's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	579.784	+	(410.964	+	25.76
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	32.016	+	0)
	=	1,049

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1659.312	-	610.788
	=	1,049

Emergent BioSolutions Total Liabilities Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines